tetano
Editor, Senior Moderator
J Infect Dis
. 2022 Mar 17;jiac099.
doi: 10.1093/infdis/jiac099. Online ahead of print.
Persistent Antibody Responses up to 18 Months after Mild SARS-CoV-2 Infection
Pyoeng Gyun Choe[SUP] 1 [/SUP], Jisu Hong[SUP] 2 3 [/SUP], Jiyoung Park[SUP] 2 3 [/SUP], Euijin Chang[SUP] 1 [/SUP], Chang Kyung Kang[SUP] 1 [/SUP], Nam Joong Kim[SUP] 1 [/SUP], Chang-Han Lee[SUP] 2 3 4 5 [/SUP], Wan Beom Park[SUP] 1 [/SUP], Myoung-Don Oh[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Humoral immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may wane rapidly in persons recovered from mild coronavirus disease 2019 (COVID-19), but little is known about the longevity.
Methods: Serum samples were obtained 8, 12, and 18 months after infection from 20 patients with mild COVID-19. The binding activities of serum antibodies (IgA, IgG, and IgM) against SARS-CoV-2 antigens of the Wuhan-1 reference strain (wild-type) and the B.1.1.7, P.1, B.1.167.2, and B.1.1.529 variants were measured by enzyme-linked immunosorbent assays. Neutralizing antibody titers were measured using a cytopathic effect-based live virus neutralization assay.
Results: Serum IgA and IgG antibodies against spike or receptor-binding domain (RBD) protein of wild-type SARS-CoV-2 were detected for up to 18 months, and neutralizing antibodies persisted for 8 to 18 months after infection. However, any significant antibody responses against RBD proteins of SARS-CoV-2 variants were not observed, and median neutralizing antibody titers against the Delta variant at 8, 12, and 18 months were 8-11 fold lower than against wild-type viruses (P < .001).
Conclusions: Humoral immunity persisted for up to 18 months after SARS-CoV-2 infection in patients with mild COVID-19. Humoral immune activity against more recently circulating variants, however, was reduced in this population.
Keywords: COVID-19; ELISA; SARS-CoV-2; neutralizing antibodies; serological response.
. 2022 Mar 17;jiac099.
doi: 10.1093/infdis/jiac099. Online ahead of print.
Persistent Antibody Responses up to 18 Months after Mild SARS-CoV-2 Infection
Pyoeng Gyun Choe[SUP] 1 [/SUP], Jisu Hong[SUP] 2 3 [/SUP], Jiyoung Park[SUP] 2 3 [/SUP], Euijin Chang[SUP] 1 [/SUP], Chang Kyung Kang[SUP] 1 [/SUP], Nam Joong Kim[SUP] 1 [/SUP], Chang-Han Lee[SUP] 2 3 4 5 [/SUP], Wan Beom Park[SUP] 1 [/SUP], Myoung-Don Oh[SUP] 1 [/SUP]
Affiliations
- PMID: 35299253
- DOI: 10.1093/infdis/jiac099
Abstract
Background: Humoral immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may wane rapidly in persons recovered from mild coronavirus disease 2019 (COVID-19), but little is known about the longevity.
Methods: Serum samples were obtained 8, 12, and 18 months after infection from 20 patients with mild COVID-19. The binding activities of serum antibodies (IgA, IgG, and IgM) against SARS-CoV-2 antigens of the Wuhan-1 reference strain (wild-type) and the B.1.1.7, P.1, B.1.167.2, and B.1.1.529 variants were measured by enzyme-linked immunosorbent assays. Neutralizing antibody titers were measured using a cytopathic effect-based live virus neutralization assay.
Results: Serum IgA and IgG antibodies against spike or receptor-binding domain (RBD) protein of wild-type SARS-CoV-2 were detected for up to 18 months, and neutralizing antibodies persisted for 8 to 18 months after infection. However, any significant antibody responses against RBD proteins of SARS-CoV-2 variants were not observed, and median neutralizing antibody titers against the Delta variant at 8, 12, and 18 months were 8-11 fold lower than against wild-type viruses (P < .001).
Conclusions: Humoral immunity persisted for up to 18 months after SARS-CoV-2 infection in patients with mild COVID-19. Humoral immune activity against more recently circulating variants, however, was reduced in this population.
Keywords: COVID-19; ELISA; SARS-CoV-2; neutralizing antibodies; serological response.
